Extemporaneous compounding of pain and symptom control medications.
This paper introduces a new series in the Journal on extemporaneously compounded dosage forms for symptom control. Some advantages and limitations of compounded medications are described and issues that clinicians should consider are mentioned. Topics that will be discussed in future papers in this series are described. Changes of compounding-related chapters of the United States Pharmacopeia from advisory statements to enforceable standards are discussed. As an example of important formulation considerations, some physical-chemical characteristics and route of administration characteristics of opioid analgesics are discussed.
Latta
Kenneth S
KS
Duke Production, Duke University Medical Center, Durham, NC 27707, USA. latta001@mc.duke.edu
D000284:Administration, Oral; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D004304:Dosage Forms / Q000592:standards; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D010146:Pain / Q000188:drug therapy*; D012995:Solubility
D000701:Analgesics, Opioid; D004304:Dosage Forms